Skip to main content
Erschienen in: Journal of Neurology 5/2012

01.05.2012 | Original Communication

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations

verfasst von: Sha Tang, Elliot L. Dimberg, Margherita Milone, Lee-Jun C. Wong

Erschienen in: Journal of Neurology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to determine the prevalence of MNGIE-like phenotype in patients with recessive POLG1 mutations. Mutations in the POLG1 gene, which encodes for the catalytic subunit of the mitochondrial DNA polymerase gamma essential for mitochondrial DNA replication, cause a wide spectrum of mitochondrial disorders. Common phenotypes associated with POLG1 mutations include Alpers syndrome, ataxia-neuropathy syndrome, and progressive external ophthalmoplegia (PEO). Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder characterized by severe gastrointestinal dysmotility, cachexia, PEO and/or ptosis, peripheral neuropathy, and leukoencephalopathy. MNGIE is caused by TYMP mutations. Rare cases of MNGIE-like phenotype have been linked to RRM2B mutations. Recently, POLG1 mutations were identified in a family with clinical features of MNGIE but no leukoencephalopathy. The coding regions and exon–intron boundaries of POLG1 were sequence analyzed in patients suspected of POLG1 related disorders. Clinical features of 92 unrelated patients with two pathogenic POLG1 alleles were carefully reviewed. Three patients, accounting for 3.3% of all patients with two pathogenic POLG1 mutations, were found to have clinical features consistent with MNGIE but no leukoencephalopathy. Patient 1 carries p.W748S and p.R953C; patient 2 is homozygous for p.W748S, and patient 3 is homozygous for p.A467T. In addition, patient 2 has a similarly affected sibling with the same POLG1 genotype. POLG1 mutations may cause MNGIE-like syndrome, but the lack of leukoencephalopathy and the normal plasma thymidine favor POLG1 mutations as responsible molecular defect.
Literatur
1.
Zurück zum Zitat Nishino I, Spinazzola A, Papadimitriou A et al (2000) Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 47(6):792–800PubMedCrossRef Nishino I, Spinazzola A, Papadimitriou A et al (2000) Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 47(6):792–800PubMedCrossRef
2.
Zurück zum Zitat Nishino I, Spinazzola A, Hirano M (1999) Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283(5402):689–692PubMedCrossRef Nishino I, Spinazzola A, Hirano M (1999) Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283(5402):689–692PubMedCrossRef
3.
Zurück zum Zitat Shaibani A, Shchelochkov OA, Zhang S et al (2009) Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. Arch Neurol 66(8):1028–1032PubMedCrossRef Shaibani A, Shchelochkov OA, Zhang S et al (2009) Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. Arch Neurol 66(8):1028–1032PubMedCrossRef
4.
Zurück zum Zitat Van Goethem G, Schwartz M, Lofgren A et al (2003) Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Eur J Hum Genet 11(7):547–549PubMedCrossRef Van Goethem G, Schwartz M, Lofgren A et al (2003) Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Eur J Hum Genet 11(7):547–549PubMedCrossRef
5.
Zurück zum Zitat Tang S, Wang J, Lee N, Milone M, Halberg MC, Schmitt ES, Craigen WJ, Zhang W, Wong LC (2011) Mitochondrial DNA polymerase γ mutations: an ever expanding molecular and clinical spectrum. J Med Genet 48(10):669–681PubMedCrossRef Tang S, Wang J, Lee N, Milone M, Halberg MC, Schmitt ES, Craigen WJ, Zhang W, Wong LC (2011) Mitochondrial DNA polymerase γ mutations: an ever expanding molecular and clinical spectrum. J Med Genet 48(10):669–681PubMedCrossRef
6.
Zurück zum Zitat Wong LJ, Naviaux RK, Brunetti-Pierri N et al (2008) Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 29(9):E150–E172PubMedCrossRef Wong LJ, Naviaux RK, Brunetti-Pierri N et al (2008) Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 29(9):E150–E172PubMedCrossRef
7.
Zurück zum Zitat Chinault AC, Shaw CA, Brundage EK et al (2009) Application of dual-genome oligonucleotide array-based comparative genomic hybridization to the molecular diagnosis of mitochondrial DNA deletion and depletion syndromes. Genet Med 11(7):518–526PubMedCrossRef Chinault AC, Shaw CA, Brundage EK et al (2009) Application of dual-genome oligonucleotide array-based comparative genomic hybridization to the molecular diagnosis of mitochondrial DNA deletion and depletion syndromes. Genet Med 11(7):518–526PubMedCrossRef
8.
Zurück zum Zitat Wong LJ, Dimmock D, Geraghty MT et al (2008) Utility of oligonucleotide array-based comparative genomic hybridization for detection of target gene deletions. Clin Chem 54(7):1141–1148PubMedCrossRef Wong LJ, Dimmock D, Geraghty MT et al (2008) Utility of oligonucleotide array-based comparative genomic hybridization for detection of target gene deletions. Clin Chem 54(7):1141–1148PubMedCrossRef
9.
Zurück zum Zitat Shanske S, Wong LJ (2004) Molecular analysis for mitochondrial DNA disorders. Mitochondrion 4(5–6):403–415PubMedCrossRef Shanske S, Wong LJ (2004) Molecular analysis for mitochondrial DNA disorders. Mitochondrion 4(5–6):403–415PubMedCrossRef
10.
Zurück zum Zitat Bai RK, Wong LJ (2005) Simultaneous detection and quantification of mitochondrial DNA deletion(s), depletion, and over-replication in patients with mitochondrial disease. J Mol Diagn 7(5):613–622PubMedCrossRef Bai RK, Wong LJ (2005) Simultaneous detection and quantification of mitochondrial DNA deletion(s), depletion, and over-replication in patients with mitochondrial disease. J Mol Diagn 7(5):613–622PubMedCrossRef
11.
Zurück zum Zitat Dimmock D, Tang LY, Schmitt ES et al (2010) Quantitative evaluation of the mitochondrial DNA depletion syndrome. Clin Chem 56(7):1119–1127PubMedCrossRef Dimmock D, Tang LY, Schmitt ES et al (2010) Quantitative evaluation of the mitochondrial DNA depletion syndrome. Clin Chem 56(7):1119–1127PubMedCrossRef
12.
Zurück zum Zitat Venegas V, Wang J, Dimmock D, et al. (2011) Real-time quantitative PCR analysis of mitochondrial DNA content. Curr Protoc Hum Genet Chapter 19:Unit 19.7 Venegas V, Wang J, Dimmock D, et al. (2011) Real-time quantitative PCR analysis of mitochondrial DNA content. Curr Protoc Hum Genet Chapter 19:Unit 19.7
13.
Zurück zum Zitat Luoma P, Melberg A, Rinne JO et al (2004) Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 364(9437):875–882PubMedCrossRef Luoma P, Melberg A, Rinne JO et al (2004) Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 364(9437):875–882PubMedCrossRef
14.
Zurück zum Zitat Milone M, Massie R (2010) Polymerase gamma 1 mutations: clinical correlations. Neurologist 16(2):84–91PubMedCrossRef Milone M, Massie R (2010) Polymerase gamma 1 mutations: clinical correlations. Neurologist 16(2):84–91PubMedCrossRef
15.
Zurück zum Zitat Cohen BH, Naviaux RK (2010) The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. Methods 51(4):364–373PubMedCrossRef Cohen BH, Naviaux RK (2010) The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. Methods 51(4):364–373PubMedCrossRef
16.
Zurück zum Zitat Taanman JW, Rahman S, Pagnamenta AT et al (2009) Analysis of mutant DNA polymerase gamma in patients with mitochondrial DNA depletion. Hum Mutat 30(2):248–254PubMedCrossRef Taanman JW, Rahman S, Pagnamenta AT et al (2009) Analysis of mutant DNA polymerase gamma in patients with mitochondrial DNA depletion. Hum Mutat 30(2):248–254PubMedCrossRef
17.
Zurück zum Zitat Deschauer M, Tennant S, Rokicka A et al (2007) MELAS associated with mutations in the POLG1 gene. Neurology 68(20):1741–1742PubMedCrossRef Deschauer M, Tennant S, Rokicka A et al (2007) MELAS associated with mutations in the POLG1 gene. Neurology 68(20):1741–1742PubMedCrossRef
18.
Zurück zum Zitat Milone M, Wang J, Liewluck T et al (2011) Novel POLG splice site mutation and optic atrophy. Arch Neurol 68(6):806–811PubMedCrossRef Milone M, Wang J, Liewluck T et al (2011) Novel POLG splice site mutation and optic atrophy. Arch Neurol 68(6):806–811PubMedCrossRef
19.
Zurück zum Zitat Santoro L, Manganelli F, Lanzillo R et al (2006) A new POLG1 mutation with peo and severe axonal and demyelinating sensory-motor neuropathy. J Neurol 253(7):869–874PubMedCrossRef Santoro L, Manganelli F, Lanzillo R et al (2006) A new POLG1 mutation with peo and severe axonal and demyelinating sensory-motor neuropathy. J Neurol 253(7):869–874PubMedCrossRef
20.
Zurück zum Zitat Nishigaki Y, Marti R, Copeland WC et al (2003) Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J Clin Invest 111(12):1913–1921PubMed Nishigaki Y, Marti R, Copeland WC et al (2003) Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J Clin Invest 111(12):1913–1921PubMed
21.
Zurück zum Zitat Giordano C, Sebastiani M, De Giorgio R et al (2008) Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion. Am J Pathol 173(4):1120–1128PubMedCrossRef Giordano C, Sebastiani M, De Giorgio R et al (2008) Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion. Am J Pathol 173(4):1120–1128PubMedCrossRef
22.
Zurück zum Zitat Vissing J, Ravn K, Danielsen ER et al (2002) Multiple mtDNA deletions with features of MNGIE. Neurology 59(6):926–929PubMedCrossRef Vissing J, Ravn K, Danielsen ER et al (2002) Multiple mtDNA deletions with features of MNGIE. Neurology 59(6):926–929PubMedCrossRef
23.
Zurück zum Zitat Hirano M, Lagier-Tourenne C, Valentino ML et al (2005) Thymidine phosphorylase mutations cause instability of mitochondrial DNA. Gene 354:152–156PubMedCrossRef Hirano M, Lagier-Tourenne C, Valentino ML et al (2005) Thymidine phosphorylase mutations cause instability of mitochondrial DNA. Gene 354:152–156PubMedCrossRef
24.
Zurück zum Zitat Pontarin G, Fijolek A, Pizzo P et al (2008) Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage. Proc Natl Acad Sci USA 105(46):17801–17806PubMedCrossRef Pontarin G, Fijolek A, Pizzo P et al (2008) Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage. Proc Natl Acad Sci USA 105(46):17801–17806PubMedCrossRef
25.
Zurück zum Zitat Bourdon A, Minai L, Serre V et al (2007) Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 39(6):776–780PubMedCrossRef Bourdon A, Minai L, Serre V et al (2007) Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 39(6):776–780PubMedCrossRef
26.
Zurück zum Zitat Tyynismaa H, Ylikallio E, Patel M et al (2009) A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. Am J Hum Genet 85(2):290–295PubMedCrossRef Tyynismaa H, Ylikallio E, Patel M et al (2009) A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. Am J Hum Genet 85(2):290–295PubMedCrossRef
27.
Zurück zum Zitat Spelbrink JN, Toivonen JM, Hakkaart GA et al (2000) In vivo functional analysis of the human mitochondrial DNA polymerase POLG expressed in cultured human cells. J Biol Chem 275(32):24818–24828PubMedCrossRef Spelbrink JN, Toivonen JM, Hakkaart GA et al (2000) In vivo functional analysis of the human mitochondrial DNA polymerase POLG expressed in cultured human cells. J Biol Chem 275(32):24818–24828PubMedCrossRef
28.
Zurück zum Zitat Milone M, Brunetti-Pierri N, Tang LY et al (2008) Sensory ataxic neuropathy with ophthalmoparesis caused by POLG mutations. Neuromuscul Disord 18(8):626–632PubMedCrossRef Milone M, Brunetti-Pierri N, Tang LY et al (2008) Sensory ataxic neuropathy with ophthalmoparesis caused by POLG mutations. Neuromuscul Disord 18(8):626–632PubMedCrossRef
29.
Zurück zum Zitat Szigeti K, Sule N, Adesina AM et al (2004) Increased blood-brain barrier permeability with thymidine phosphorylase deficiency. Ann Neurol 56(6):881–886PubMedCrossRef Szigeti K, Sule N, Adesina AM et al (2004) Increased blood-brain barrier permeability with thymidine phosphorylase deficiency. Ann Neurol 56(6):881–886PubMedCrossRef
30.
Zurück zum Zitat Hirano M, Silvestri G, Blake DM et al (1994) Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 44(4):721–727PubMedCrossRef Hirano M, Silvestri G, Blake DM et al (1994) Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 44(4):721–727PubMedCrossRef
31.
Zurück zum Zitat Amiot A, Tchikviladze M, Joly F et al (2009) Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction. Gastroenterology 137(1):101–109PubMedCrossRef Amiot A, Tchikviladze M, Joly F et al (2009) Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction. Gastroenterology 137(1):101–109PubMedCrossRef
32.
Zurück zum Zitat Chinnery PF, Turnbull DM (1997) Clinical features, investigation, and management of patients with defects of mitochondrial DNA. J Neurol Neurosurg Psychiatry 63(5):559–563PubMedCrossRef Chinnery PF, Turnbull DM (1997) Clinical features, investigation, and management of patients with defects of mitochondrial DNA. J Neurol Neurosurg Psychiatry 63(5):559–563PubMedCrossRef
33.
Zurück zum Zitat Kapur RP, Fligner C, Maghsoodi B et al (2011) Gastrointestinal neuromuscular pathology in alpers disease. Am J Surg Pathol 35(5):714–722PubMedCrossRef Kapur RP, Fligner C, Maghsoodi B et al (2011) Gastrointestinal neuromuscular pathology in alpers disease. Am J Surg Pathol 35(5):714–722PubMedCrossRef
34.
Zurück zum Zitat Marti’ R, Verschuuren JJGM, Buchman A et al (2005) Late-oset MNGIE due to partial loss of thymidine phosphorylase activity. Ann Neurol 58(4):649–652CrossRef Marti’ R, Verschuuren JJGM, Buchman A et al (2005) Late-oset MNGIE due to partial loss of thymidine phosphorylase activity. Ann Neurol 58(4):649–652CrossRef
35.
Zurück zum Zitat Echaniz-Laguna A, Chassagne M, de Sèze J et al (2010) POLG1 variations presenting as multiple sclerosis. Arch Neurol 67(9):1140–1143PubMedCrossRef Echaniz-Laguna A, Chassagne M, de Sèze J et al (2010) POLG1 variations presenting as multiple sclerosis. Arch Neurol 67(9):1140–1143PubMedCrossRef
Metadaten
Titel
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations
verfasst von
Sha Tang
Elliot L. Dimberg
Margherita Milone
Lee-Jun C. Wong
Publikationsdatum
01.05.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 5/2012
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-011-6268-6

Weitere Artikel der Ausgabe 5/2012

Journal of Neurology 5/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.